Richards Group Inc. announces unaudited 2025 Results: Revenue growth of 5.5% primarily on acquisitions; new segmented reporting for Healthcare and Packaging

Executive Summary

• Richards Group reported total revenue of $430.2 M for FY 2025, up 5.5% year‑over‑year driven primarily by acquisitions.
• Adjusted EBITDA fell to $54.8 M (down 3.7%) as higher administrative costs and a steep packaging decline offset healthcare growth.
• The company disclosed three acquisitions totaling $63.3 M (including $5.0 M contingent consideration) and announced a new $115 M revolving credit facility for working‑capital and future acquisitions.

Key Details

• Revenue Highlights
• FY 2025 total revenue: $430.2 M (+5.5% YoY).
• Q4 2025 revenue: $110.9 M (+5.8% YoY).

• Healthcare segment organic revenue fell $6.3 M (-3.2%) to $189.0 M; Packaging segment organic revenue fell $4.4 M (-2.1%) to $208.1 M.

• Profitability

• Adjusted EBITDA FY 2025: $54.8 M (‑3.7% YoY).
• Adjusted EBITDA Q4 2025: $14.8 M (‑3.6% YoY).

• Adjusted EBITDA margin FY 2025: 12.7%; Q4 2025: 13.3%.

• Acquisitions & Separately Disclosed Items

• Three acquisitions for a total purchase price of $63.3 M plus contingent consideration of $5.0 M.

• Separately disclosed items FY 2025 = $7.8 M (acquisition costs $2.2 M, corporate conversion $0.8 M, patent dispute defense $1.9 M, wire‑fraud loss $1.2 M, management termination $0.3 M, fair‑value inventory adjustments $1.4 M).

• Balance Sheet & Liquidity

• Net debt at year‑end: $52.8 M (leverage 0.96× Adjusted EBITDA).
• Working capital: $90.1 M (driven by acquisition‑related inventory).

• Cash & cash equivalents: –$5.9 M (negative due to acquisitions and dividend payments).

• Cash Flow

• Adjusted free cash flow FY 2025: $35.0 M, allocated to dividends ($15.1 M), debt repayments ($12.4 M) and the $7.8 M of separately disclosed items.

• Dividend: monthly 11¢ per share (annual yield ~4.3%, payout ratio 43%).

• Financing

• On 2026‑01‑01, revolving credit facility amended to $115 M at a cost of $0.3 M; available for working capital and future acquisitions.

• Leverage covenant: debt < 2.75× trailing twelve‑month Adjusted EBITDA; actual leverage 0.94× as of 2025‑12‑31.

• Segment Reporting Change

• Company now reports two operating segments – Healthcare and Packaging – replacing the prior single‑segment format.

• Operational Highlights

• Healthcare segment: revenue +14% YoY, gross margin +25%; strong growth in vision care and surgical lasers; aesthetics organic decline offset by mix shift.

• Packaging segment: revenue down 16% Q4, 2.1% FY; gross margin modestly improved to 38.4% through cost‑control and focus on core small‑business customers.

• Management Commentary (optional)

• CEO John Glynn emphasized that acquisition‑driven growth offsets organic declines and that the new credit facility positions the company for continued strategic expansion.

All figures are unaudited unless otherwise noted.